Discovery of a potent picolinamide antibacterial active against Clostridioides difficile.
暂无分享,去创建一个
S. Mobashery | J. Fisher | E. Lastochkin | Jeshina Janardhanan | Valerie A. Schroeder | W. Wolter | Mayland Chang | César A. Masitas | Enrico Speri
[1] Antibiotic resistance threats in the United States, 2019 , 2019 .
[2] H. Tilg,et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice , 2019, Gut.
[3] S. Mobashery,et al. Cinnamonitrile Adjuvants Restore Susceptibility to β-Lactams against Methicillin-Resistant Staphylococcus aureus. , 2019, ACS medicinal chemistry letters.
[4] M. Rai,et al. Updates in Treatment of Recurrent Clostridium difficile Infection , 2019, Journal of clinical medicine research.
[5] E. Kuijper,et al. Clostridium difficile infection: review , 2019, European Journal of Clinical Microbiology & Infectious Diseases.
[6] T. Louie,et al. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. , 2019, The Lancet. Infectious diseases.
[7] N. Petrosillo,et al. Novel Antimicrobials for the Treatment of Clostridium difficile Infection , 2018, Front. Med..
[8] R. Fedorak,et al. Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection , 2017, Open forum infectious diseases.
[9] C. Kelly,et al. Predictors of Early Failure After Fecal Microbiota Transplantation for the Therapy of Clostridium Difficile Infection: A Multicenter Study , 2016, The American Journal of Gastroenterology.
[10] L. Chesnel,et al. Mode of Action and Bactericidal Properties of Surotomycin against Growing and Nongrowing Clostridium difficile , 2015, Antimicrobial Agents and Chemotherapy.
[11] D. Leffler,et al. Clostridium difficile infection. , 2015, The New England journal of medicine.
[12] M. Suckow,et al. Discovery of antibiotic (E)-3-(3-carboxyphenyl)-2-(4-cyanostyryl)quinazolin-4(3H)-one. , 2015, Journal of the American Chemical Society.
[13] Bo Li,et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection , 2014, Nature Communications.
[14] P. Caspers,et al. Investigations of the Mode of Action and Resistance Development of Cadazolid, a New Antibiotic for Treatment of Clostridium difficile Infections , 2013, Antimicrobial Agents and Chemotherapy.
[15] A. Sonenshein,et al. Fidaxomicin inhibits toxin production in Clostridium difficile. , 2013, The Journal of antimicrobial chemotherapy.
[16] A. Sonenshein,et al. Fidaxomicin Inhibits Spore Production in Clostridium difficile , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] M. Falagas,et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. , 2012, International journal of antimicrobial agents.
[18] J. Rood,et al. The role of toxin A and toxin B in the virulence of Clostridium difficile. , 2012, Trends in microbiology.
[19] Pamela Sears,et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.
[20] Jeffrey D Goldsmith,et al. A mouse model of Clostridium difficile-associated disease. , 2008, Gastroenterology.
[21] C. Kelly,et al. Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.
[22] H. Dupont,et al. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] L. Sabath,et al. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] D. Livermore. Linezolid in vitro: mechanism and antibacterial spectrum. , 2003, The Journal of antimicrobial chemotherapy.
[25] A. Tomasz,et al. In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae , 1980, Antimicrobial Agents and Chemotherapy.